Posted On: 12/18/2015 6:46:32 PM
Post# of 72448
As the subject of the broad range of diratives covered by the Kevetrin Patent came up elsewhere I ran across this article again. Definitely worth a read.
"As a general rule, Big Pharmas express little interest in a compound until human data are released in Phase I or later studies. Kevetrin is an exception to this rule. Already, several big players have expressed interest, and one multibillion-dollar drug maker has even signed a nondisclosure agreement based on the strength of the preclinical data.
Ehrlich, however, tells us that Cellceutix is in no hurry to partner until the company is in a stronger position. While some investors might hope for an early Big Pharma deal, yields are maximized by taking drug candidates through the clinical trials process. This reduces risk for pharmas and increases competition among them for a partnership agreement. Phase I trials are usually the smallest and least expensive to run, and Ehrlich believes the company has the financial strength to carry it out on its own. This is good news for Cellceutix investors.
Kevetrin also has a strong intellectual property position. In the biotechnology business, strong patent protections are often the difference between success and failure. The patent for Kevetrin was published last year, and was written by Dr. Paul Ginsburg. Dr. Ginsburg, a patent attorney, has worked in senior positions at Pfizer and Schering. Among other important pharmaceutical patents, he wrote Claritin’s. It has never been challenged.
Moreover, because this class of chemicals has never been used in medicine, research into other pharmaceutical uses has barely begun. The number of potential uses is, in fact, vast. Cellceutix’s patent covers tens of thousands of possible chemical combinations for therapeutic use.
http://www.hotstockmarket.com/t/259020/ctix-c...orporation
"As a general rule, Big Pharmas express little interest in a compound until human data are released in Phase I or later studies. Kevetrin is an exception to this rule. Already, several big players have expressed interest, and one multibillion-dollar drug maker has even signed a nondisclosure agreement based on the strength of the preclinical data.
Ehrlich, however, tells us that Cellceutix is in no hurry to partner until the company is in a stronger position. While some investors might hope for an early Big Pharma deal, yields are maximized by taking drug candidates through the clinical trials process. This reduces risk for pharmas and increases competition among them for a partnership agreement. Phase I trials are usually the smallest and least expensive to run, and Ehrlich believes the company has the financial strength to carry it out on its own. This is good news for Cellceutix investors.
Kevetrin also has a strong intellectual property position. In the biotechnology business, strong patent protections are often the difference between success and failure. The patent for Kevetrin was published last year, and was written by Dr. Paul Ginsburg. Dr. Ginsburg, a patent attorney, has worked in senior positions at Pfizer and Schering. Among other important pharmaceutical patents, he wrote Claritin’s. It has never been challenged.
Moreover, because this class of chemicals has never been used in medicine, research into other pharmaceutical uses has barely begun. The number of potential uses is, in fact, vast. Cellceutix’s patent covers tens of thousands of possible chemical combinations for therapeutic use.
http://www.hotstockmarket.com/t/259020/ctix-c...orporation
(0)
(0)
